Browsing Tag
iptacopan
4 posts
Will multi-year kidney function data secure Vanrafia’s long-term positioning?
Novartis Pharma AG’s ALIGN data test whether eGFR slope preservation can confirm Vanrafia’s clinical benefit. Read the full executive analysis.
Will Novartis’ oral drug iptacopan change the game in myasthenia gravis treatment?
Novartis gains FDA orphan designation for iptacopan in myasthenia gravis. Explore how this oral drug could shift neurology and rare disease strategy.
Novartis wins FDA approval for Fabhalta, the first treatment for C3 glomerulopathy
Novartis secures FDA approval for Fabhalta, the first-ever treatment for C3G. Find out how this breakthrough impacts patients and investors.
Novartis reports significant proteinuria reduction by Fabhalta in Phase 3 IgAN trial
Novartis has shared encouraging results from the Phase III APPLAUSE-IgAN study, revealing that Fabhalta (iptacopan) led to a…